TB Notes 4, 2018 - Updates from CDC’s Division of Tuberculosis Elimination

TB Notes 4, 2018 July 31, 2018

Table of Contents Communications, Education and Behavioral Branch Updates Field Services Branch Laboratory Branch Updates Clinical Research Branch Updates TB Notes Subscription and Article Submission Process New CDC Publications Notes from the Director Dear Colleague: The Centers for Disease Control and Prevention (CDC) released updated recommendations for the use of once-weekly isoniazid-rifapentine for 12 weeks (3HP) for the treatment of latent tuberculosis (TB) infection. The updated recommendations, published in CDC’s Morbidity and Mortality Weekly Report (MMWR)

Communications, Education and Behavioral Branch Updates New Team Lead We are pleased to announce that Allison Maiuri, MPH, CHES, is the new team leader for the Education, Training, and Behavioral Studies Team within the Communications, Education, and Behavioral Studies Branch (CEBSB) in the Division of Tuberculosis Elimination (DTBE). Read More Field Services Branch New York City TB Summit On June 29th, the New York City Department of Health and Mental Hygiene’s first-ever TB Summit gathered 200 policy makers, thought leaders, innovators, TB survivors, and public health experts to kick off strategic efforts towards eliminating TB in New York City (NYC).  The NYC TB rate is still more than double the national rate (7.5 vs 2.8 cases per 100,000 persons in 2017). Read More Laboratory Branch Updates After Hurricane Maria, the Puerto Rico Department of Health (PRDOH) Tuberculosis (TB) Laboratory, with the assistance of DTBE, CDC Foundation, CDC’s Emergency Operations Center, and the Association of Public Health Laboratories, began sending samples from patients at high risk for TB disease to CDC.  Read More Clinical Research Branch Updates Several key staff from the Clinical Research Branch (CRB) attended the Network meeting of the AIDS Clinical Trials Group (ACTG) in Washington DC in June.  ACTG is collaborating with the Division of Tuberculosis Elimination (DTBE) and Tuberculosis Trials Consortium (TBTC) in the conduct of Study 31/A5349, which is assessing a 4-month regimen based on high dose daily Rifapentine for treatment of active TB disease.  Read More TB Notes Subscription and Article Submission Process To receive the TB Notes Newsletter, enter your email address at the bottom of the TB Notes webpage. If you would like to submit an article or update in TB Notes, please email Sloane Bowman at wnv2@cdc.gov. You can follow us on Twitter @CDC_TB and Facebook @CDCTB and sign up for email updates through GovDelivery. New CDC Publications Cohn DL, El Sadr WM, Abrams DI, Neaton JD, Benator DA, Vernon AA. In memoriam, Fred Gordin, MD, 1951–2018. Clin Infect Dis 2018. Epub ahead of print. Njie GJ, Bamrah Morris S, Yelk Woodruff R, Moro RN, Vernon AA, Borisov AS. Isoniazid-rifapentine for latent tuberculosis infection: a systematic review and meta-analysis. Am J Prev Med 2018. Epub ahead of print. (Moro, also with the CDC Foundation Research Collaboration). Stockbridge EL, Miller TL, Carlson EK, Ho C. Predictors of latent tuberculosis infection treatment completion in the US private sector: an analysis of administrative claims data. BMC Public Health 2018;18:662.